Relief Therapeutics Holding AG (RLFTF)

[tcm55]

Page 1; NeuroRx recently announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of RLF-100, or “ZYESAMI”, an application for COVID-related respiratory failure (the “NeuroRx COVID-19 Drug”). NeuroRx is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior (the “NeuroRx Antidepressant Drug Regimen”).


The JEWEl of the DEAL IS RLF-100, the other drug is fluff.